CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population

Acta Neuropathol Commun. 2023 Feb 13;11(1):26. doi: 10.1186/s40478-023-01523-y.

Abstract

The Central Nervous System (CNS) tumor with BCOR internal tandem duplication (ITD) has recently been added as a novel embryonal histomolecular tumor type to the 2021 World Health Organization (WHO) Classification of CNS Tumors. In addition, other CNS tumors harboring a BCOR/BCORL1 fusion, which are defined by a distinct DNA-methylation profile, have been recently identified in the literature but clinical, radiological and histopathological data remain scarce. Herein, we present two adult cases of CNS tumors with EP300::BCOR fusion. These two cases presented radiological, histopathological, and immunohistochemical homologies with CNS tumors having BCOR ITD in children. To compare these tumors with different BCOR alterations, we performed a literature review with a meta-analysis. CNS tumors with EP300::BCOR fusion seem to be distinct from their BCOR ITD counterparts in terms of age, location, progression-free survival, tumor growth pattern, and immunopositivity for the BCOR protein. CNS tumors from the EP300::BCOR fusion methylation class in adults may be added to the future WHO classification.

Keywords: Adult; BCOR; EP300.

Publication types

  • Review
  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers, Tumor / analysis
  • Central Nervous System Neoplasms* / genetics
  • Child
  • E1A-Associated p300 Protein / genetics
  • Humans
  • Prevalence
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism
  • Repressor Proteins / genetics

Substances

  • Biomarkers, Tumor
  • BCOR protein, human
  • Proto-Oncogene Proteins
  • Repressor Proteins
  • EP300 protein, human
  • E1A-Associated p300 Protein